Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
osmotic diuretic
|
| gptkbp:brand |
gptkb:Osmitrol
|
| gptkbp:clinical_trial |
Phase IV
intensive care unit emergency medicine neurosurgery urological surgery ophthalmic surgery |
| gptkbp:contraindication |
pulmonary edema
active intracranial bleeding severe renal disease |
| gptkbp:current_use |
gptkb:sneaker
traumatic brain injury acute kidney injury cardiac surgery cerebral edema |
| gptkbp:effective_date |
gptkb:1960
FDA approved |
| gptkbp:formulation |
solution for injection
|
| https://www.w3.org/2000/01/rdf-schema#label |
Osmitrol
|
| gptkbp:ingredients |
C6 H14 O6
|
| gptkbp:interacts_with |
gptkb:digoxin
lithium antihypertensives other diuretics aminoglycosides |
| gptkbp:is_atype_of |
C05 B
|
| gptkbp:is_used_for |
promoting diuresis
reducing intracranial pressure treating oliguric renal failure |
| gptkbp:level |
5.0 to 7.0
|
| gptkbp:manager |
intravenous
|
| gptkbp:manufacturer |
gptkb:Baxter_International
|
| gptkbp:packaging |
vials
|
| gptkbp:pharmacokinetics |
excreted unchanged in urine
draws fluid from tissues into circulation duration of action 3-8 hours increases osmolarity of blood increases urine output onset of action within 15 minutes peak effect within 30-60 minutes |
| gptkbp:previous_name |
gptkb:Mannitol
|
| gptkbp:side_effect |
headache
nausea electrolyte imbalance vomiting dehydration |
| gptkbp:storage |
room temperature
|
| gptkbp:threats |
monitor renal function
administer slowly avoid rapid infusion monitor electrolyte levels |
| gptkbp:type_of |
69-65-8
|
| gptkbp:weight |
182.17 g/mol
|
| gptkbp:bfsParent |
gptkb:Mannitol
|
| gptkbp:bfsLayer |
5
|